Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Sarepta Therapeutics (SRPT)
NASDAQ:SRPT
SRPT Stock Chart & Stats
Day’s Range― - ―
52-Week Range$101.15 - $173.25
Previous CloseN/A
Volume185.86K
Average Volume (3M)835.04K
Market Cap
$10.06B
Enterprise Value$12.74B
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)89.0
Beta0.81
Next Earnings
Feb 26, 2025EPS Estimate
1.92Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.20
Shares Outstanding95,519,650
10 Day Avg. Volume786,990
30 Day Avg. Volume835,039
Standard Deviation0.14
R-Squared0.08
Alpha0.00198
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)6.13
Price to Cash Flow (P/CF)-35.60
P/FCF Ratio0.00
Enterprise Value/Market Cap1.27
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit11.66
Enterprise Value/Ebitda70.84
Forecast
1Y Price Target
$179.17Price Target Upside67.26% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering15
---
Bulls Say, Bears Say
Bulls Say
Clinical DataGrowing clinical data and experience can enhance Elevidys's commercial uptake and positively influence potential EU approval.
Market PositioningSarepta is well-positioned to leverage its expertise and market leadership in driving Elevidys revenue growth, with no significant near-term competitors.
Safety ProfileElevidys has continued to demonstrate a clean safety profile and there is encouragement by the momentum of the launch.
Bears Say
Coverage LimitationsThere could be a considerable lack of coverage for the nonambulatory and older DMD patient populations, leading to a limited total addressable market (TAM) for ELEVIDYS.
Payer RejectionsSome payers have rejected label expansion coverage for Elevidys beyond the initial label population of ambulatory DMD patients ages 4-5.
Study Design ConcernsUpdated Elevidys Phase 3 EMBARK results draw questions, raising concerns about the effectiveness of the study's design.
---
Ownership Overview
4.10% Insiders
31.20% Mutual Funds
32.89% Other Institutional Investors
11.30% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
SRPT FAQ
What was Sarepta Therapeutics’s price range in the past 12 months?
Sarepta Therapeutics lowest stock price was $101.15 and its highest was $173.25 in the past 12 months.
What is Sarepta Therapeutics’s market cap?
Sarepta Therapeutics’s market cap is $10.06B.
When is Sarepta Therapeutics’s upcoming earnings report date?
Sarepta Therapeutics’s upcoming earnings report date is Feb 26, 2025 which is in 5 days.
How were Sarepta Therapeutics’s earnings last quarter?
Sarepta Therapeutics released its earnings results on Nov 06, 2024. The company reported $0.34 earnings per share for the quarter, beating the consensus estimate of -$0.075 by $0.415.
Is Sarepta Therapeutics overvalued?
According to Wall Street analysts Sarepta Therapeutics’s price is currently Undervalued.
Does Sarepta Therapeutics pay dividends?
Sarepta Therapeutics does not currently pay dividends.
What is Sarepta Therapeutics’s EPS estimate?
Sarepta Therapeutics’s EPS estimate is 1.92.
How many shares outstanding does Sarepta Therapeutics have?
Sarepta Therapeutics has 95,519,650 shares outstanding.
What happened to Sarepta Therapeutics’s price movement after its last earnings report?
Sarepta Therapeutics reported an EPS of $0.34 in its last earnings report, beating expectations of -$0.075. Following the earnings report the stock price went down -5.9%.
Which hedge fund is a major shareholder of Sarepta Therapeutics?
Currently, no hedge funds are holding shares in SRPT
---
Sarepta Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$179.17 (67.26% Upside)
$179.17 (67.26% Upside)
Blogger Sentiment
Bullish
SRPT Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 9.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.5M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▲ 0.2%
Last 30 Days ▼ 0.2%
Last 30 Days ▼ 0.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-20.42%
12-Months-Change
Fundamentals
Return on Equity
12.27%
Trailing 12-Months
Asset Growth
15.76%
Trailing 12-Months
Company Description
Sarepta Therapeutics
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980 and is headquartered in Cambridge, MA.
---
SRPT Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted strong revenue growth and sustained profitability, driven by the impressive performance of ELEVIDYS and the PMO franchise. Despite the setback of discontinuing the SRP-5051 program, Sarepta's financial health remains robust, and confidence in future performance is high.Read More>---
SRPT Stock 12 Month Forecast
Average Price Target
$179.17
▲(67.26% Upside)
Technical Analysis
BioMarin Pharmaceutical
―
Exelixis
―
Vertex Pharmaceuticals
―
PTC Therapeutics
―
Ultragenyx Pharmaceutical
―
Best Analysts Covering SRPT
1 Year
1 Year Success Rate
29/47 ratings generated profit
1 Year Average Return
+13.77%
reiterated a buy rating 4 months ago
Copying Brian Skorney's trades and holding each position for 1 Year would result in 61.70% of your transactions generating a profit, with an average return of +13.77% per trade.
---